Related Experiment Videos
The Interleukin 1-beta exonic (+3953) polymorphism does not alter in vitro protein secretion
Roberto Dominici1, Giulia Malferrari, Claudio Mariani
1Institute of Biomedical Sciences, Department of Neurology, Ospedale Luigi Sacco, Milan, Italy
Experimental and Molecular Pathology
|September 17, 2002
Summary
Interleukin-1 beta gene variations may influence Alzheimer disease risk. This study examined the interleukin-1 beta exonic polymorphism (+3953) in healthy individuals and through in vitro assays.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Polymorphisms in interleukin-1alpha (IL-1alpha) and interleukin-1beta (IL-1beta) genes are linked to Alzheimer disease (AD).
- Previous findings primarily associate these genetic variations with sporadic forms of AD.
- The precise role of IL-1beta genetic variants in AD pathogenesis requires further elucidation.
Purpose of the Study:
- To investigate the impact of the interleukin-1 beta exonic polymorphism (+3953) on AD.
- To analyze the effects of this polymorphism in healthy control cohorts.
- To assess protein secretion in vitro related to the IL-1beta polymorphism.
Main Methods:
- Analysis of a series of healthy control samples.
- In vitro protein secretion assays.
- Genotyping for the interleukin-1 beta exonic polymorphism (+3953).
Main Results:
- Data presented on the effects of the interleukin-1 beta exonic polymorphism (+3953).
- Results derived from healthy control cohorts.
- Findings from in vitro protein secretion assays are detailed.
Conclusions:
- The study provides data on the interleukin-1 beta exonic polymorphism (+3953).
- Further research is warranted to fully understand the implications of IL-1beta gene variations in Alzheimer disease.
- The findings contribute to the ongoing investigation of genetic factors in AD.